Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 3Uterine Cervical Neoplasms 2Vaginal Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Lung Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma 1Adenocarcinoma 1

Interventions

Gemcitabine 3Nivolumab 2temoporfin 1spartalizumab 1polysaccharide-K 1pembrolizumab 1nimotuzumab 1devimistat 1dalotuzumab 1bemarituzumab 1belinostat 1Transurethral Resection of Prostate 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiofrequency Ablation 1Oxaliplatin 1Morphine 1Methadone 1Leucovorin 1Ipilimumab 1Interviews as Topic 1Injections 1Immunotherapy 1Heavy Ion Radiotherapy 1Fluorouracil 1Erlotinib Hydrochloride 1Docetaxel 1Cryosurgery 1Cisplatin 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Adenocarcinoma × Brachytherapy × Clear all
NCT01301612 2014-07-14

Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)

Eurofarma Laboratorios S.A.

Phase 2 Withdrawn
Tumor-Agnostic

Adenocarcinoma, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡